SCHEMBL30294266

SCHEMBL30294266

CCOC(=O)c1cc(C)ccc1Nc1ccc(F)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 3/20 0.49
KDM4E B2RXH2 3/20 0.49
MAPT P10636 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
TP53 P04637 2/20 0.47
MRGPRX1 Q96LB2 2/20 0.47
TSHR P16473 1/20 0.46
MAP2K2 P36507 1/20 0.45
MAP2K1 Q02750 1/20 0.45
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
THRB P10828 1/20 0.44
CDC25B P30305 2/20 0.43
CDC25A P30304 1/20 0.43
CDC25C P30307 1/20 0.43
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853409 1.00 SMN1; SMN2 (0.50) SMN1; SMN2LMNAKDM4EMAPTNPSR1
SCHEMBL30294796 0.87 MAPT (0.50) SMN1; SMN2LMNAKDM4EMAPTTP53
SCHEMBL22853357 0.87 MAPT (0.50) SMN1; SMN2LMNAKDM4EMAPTTP53
SCHEMBL22853414 0.85 MRGPRX4 (0.45) SMN1; SMN2LMNAKDM4ETSHRPOLB
SCHEMBL30294513 0.85 MRGPRX4 (0.45) SMN1; SMN2LMNAKDM4ETSHRPOLB
SCHEMBL22853362 0.84 MAP2K1 (0.44) SMN1; SMN2LMNAKDM4ENPSR1TSHR
SCHEMBL30294529 0.82 DHODH (0.56) DHODH
SCHEMBL22852994 0.82 DHODH (0.56) DHODH
SCHEMBL22853397 0.81 MAPT (0.49) SMN1; SMN2LMNAKDM4EMAPTTP53
SCHEMBL30294784 0.81 MAPT (0.49) SMN1; SMN2LMNAKDM4EMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B SMN1; SMN2 195/4885LMNA 686/4885KDM4E 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.